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Background: West Nile Virus (WNV) is an emerging arthropod-born flavivirus with increasing distribution worldwide
that is responsible for a large proportion of viral encephalitis in humans and horses. Given that there are no effective
antiviral drugs available for treatment of the disease, efforts have been directed to develop vaccines to prevent WNV
infection. Recently baculovirus has emerged as a novel and attractive gene delivery vehicle for mammalian cells.
Results: In the present study, recombinant baculoviruses expressing WNV premembrane (prM) and envelope (E)
proteins under the cytomegalovirus (CMV) promoter with or without vesicular stomatitis virus glycoprotein (VSV/G)
were constructed. The recombinant baculoviruses designated Bac-G-prM/E and Bac-prM/E, efficiently express E protein
in mammalian cells. Intramuscular injection of the two recombinant baculoviruses (at doses of 108 or 109 PFU/mouse)
induced the production of WNV-specific antibodies, neutralizing antibodies as well as gamma interferon (IFN-γ) in a
dose-dependent pattern. Interestingly, the recombinant baculovirus Bac-G-prM/E was found to be a more efficient
immunogen than Bac-prM/E to elicit a robust immune response upon intramuscular injection. In addition, inoculation
of baculovirus resulted in the secretion of inflammatory cytokines, such as TNF-α, IL-2 and IL-6.
Conclusions: These recombinant baculoviruses are capable of eliciting robust humoral and cellular immune responses
in mice, and may be considered as novel vaccine candidates for West Nile Virus.
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West Nile Virus (WNV), a mosquito-born virus, belongs
to the Japanese encephalitis serogroup of flaviviruses [1]
and is an outstanding example of a zoonotic pathogen as
its geographic range spans North and South America,
Europe, the Middle East, Africa, Western Asia and Aus-
tralia [2,3]. Zoonotic transmission of WNV involves Culex
mosquitos and birds as the natural reservoir hosts, with
humans and horses as dead-end hosts [4]. WNV infec-
tions are ranging from a sub-clinical illness, to a self-* Correspondence: sbcao@mail.hzau.edu.cn
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reproduction in any medium, provided the orlimiting febrile syndrome or a lethal neuroinvasive disease,
and the incidence of severe disease and death increases
with age [5,6]. Since the emergence of WNV in north
American in 1999, WNV has been responsible for over
12,000 cases of meningitis/encephalitis, and over 1,100
fatalities in humans and mass mortality of resident birds
[7]. The arbovirus infection of humans and animals is be-
coming a major public health and veterinary concern [4].
The WNV outbreak in North America coupled with the
absence of specific therapy against WNV infection has
triggered vaccine development to prevent the infection of
humans and animals. It has been shown that virion enve-
lope is embedded with viral envelope (E) and premem-
brane/membrane (prM/M) proteins. The prM protein
helps proper folding of the E protein by forming. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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The glycoprotein E is responsible for many properties of
the virus including host range, replication, assembly, and
stimulation of humoral and cellular immune responses
[11]. A variety of WNV vaccine candidates based on the
glycoprotein E, which evokes the majority of the neutraliz-
ing antibodies, have been developed. Three equine vac-
cines have been successfully commercialized in the USA,
including InnovatorTM, formulated based on formalin-
inactivated virus, RecombitekTM, a recombinant replica-
tive canarypoxvirus vaccine, and pCBWN, a recombinant
plasmid DNA vaccine [12]. Novel recombinant subunit
vaccine candidates such as virus-like particles (VLPs), vec-
toring vaccine candidates, DNA vaccine candidates [12],
and TripliVAX JE, a chimeric vaccine expressing prM/E
and NS1 gene of Japanese encephalitis virus [13], have
shown protective immunity in animal model. However,
there are no vaccines currently available for humans. With
the growing volume of international travel and commerce,
exotic pathogens can spread quickly between continents.
Therefore, safe and effective vaccines of WNV are needed
for humans.
In recent years, baculovirus has emerged as a vector
for gene delivery and vaccine development, with promis-
ing newcomer being Autographa californica multiple
nucleopolyhedrovirus (AcMNPV), a member of baculo-
viridae family. The host specificity of baculovirus was
originally thought to be restricted to cells derived from a
few taxonomically related insect species [14]. However,
it has been shown to infect a number of mammalian
cells without replication [15-18]. Additionally, accumu-
lated evidence has revealed that baculovirus express for-
eign proteins not only in insect cells, but also in
mammalian cells under the transcriptional control of
mammalian promoters [14,16,19]. Subsequently, it has
been reported that a baculovirus pseudotyped with the
glycoprotein (G) of the vesicular stomatitis virus (VSV/
G) appeared to help the virus escape from the endo-
somes, which increases transduction efficiency in mam-
malian cells [20,21]. Furthermore, the baculovirus hasFigure 1 Schematic presentation for the construction of the recombin
plasmids were derived from pFastBac1 and pFastBac-VSV/G as described in
driven by the CMV immediate-early promoter (PCMV indicated by a red arro
polyhedrin promoter of baculovirus (polh); polyA, polyadenylation signal.advantages of being a strong adjuvant and thus can in-
duce inflammatory cytokines and interferons [22-24]. To
this end, several studies have demonstrated that direct
vaccination with recombinant baculovirus can induce
high-level humoral and cell-mediated immunity against
various antigens, including pseudorabies virus glycopro-
tein B (gB) [25], GP5 and M protein of porcine repro-
ductive and respiratory syndrome virus (PRRSV) [26],
capsid protein of procine circovirus type2 [27], rabies
virus glycoprotein [28] and Japanese encephalitis virus
(JEV) envelope protein [29].
In the present study, recombinant baculoviruses
expressing WNV prM and E protein were constructed
with or without pseudotyping with VSV/G. Protein ex-
pression was characterized in transduced mammalian
cells and its immunogenicity was investigated in a
mouse model. The results showed that direct
immunization with the recombinant baculoviruses
induced a higher level of WNV-specific antibody, neu-
tralizing antibody and gamma interferon compared with
E-DIII protein vaccine, suggesting that the recombinant
baculoviruses expressing WNV prM and E protein could
be developed as new vaccine candidates for WNV.
Results
Construction of recombinant baculoviruses expressing
WNV protein
Recombinant baculovirus has been used as gene-delivery
vehicles for transient expression of recombinant proteins
in mammalian cells. In the present study, recombinant
baculoviruses Bac-prM/E and Bac-G-prM/E expressing
WNV prM and E gene under the control of the cyto-
megalovirus immediate early promoter were constructed
(Figure 1).
In order to investigate the transduction efficiency of
the constructed recombinant baculoviruses Bac-prM/E
and Bac-G-prM/E. BHK-21 cells were transduced with
the constructed baculoviruses or control baculovirus
(Bac-G-EGFP or Bac-EGFP) at a multiplicity of infection
(MOI) of 100. An indirect immunofluorescence assayation baculoviruses used in this study. Baculovirus transfer
Materials and Methods. The expression of prM/E genes of WNV is
w). VSV/G, the glycoprotein of vesicular stomatitis virus, is driven by
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transduction to measure the level of WNV protein ex-
pression in mammalian cells. As shown in Figure 2A,
significant fluorescence was detected in Bac-prM/E- and
Bac-G-prM/E- transducd BHK-21 cells, whereas it wasFigure 2 Expression of WNV protein in baculovirus-transduced cells. (
Bac-G-EGFP (A-3), or Bac-EGFP (A-4), at a MOI of 100. At 48h post-transduction
using monoclonal antibodies against WNV E-DIII protein, followed by fluoresc
taken with a fluorescence microscope (400× original magnification). (B) BHK-2
Bac-G-EGFP (lane 3), or Bac-EGFP (lane 4). Total cell lysates were prepared at 4
Materials and Methods. Cell lysates from mock-transduced (lane 5) BHK-21 ce
standards (in kilodaltons) were indicated. (C) Comparison of the transduction
with Bac-G-prM/E (lane1-3) or Bac-prM/E (lane 4–6) at MOIs of 10, 50, and 100not detected in the Bac-EGFP- or Bac-G-EGFP- trans-
duced cells. A protein band of approximately 55 KDa
was consistently observed in recombinant baculovirus-
transduced BHK-21 cell lysates as detected by Western
blotting (Figure 2B). BHK-21 cells were also transducedA) BHK-21 cells were transduced with Bac-G-prM/E (A-1), Bac-prM/E (A-2),
, the cells were fixed and immunofluorescence assay was conducted
ein isocyanate-conjugated goat anti-mouse IgG. Fluorescent images were
1 cells were transduced with Bac-G-prM/E (lane 1), Bac-prM/E (lane 2),
8 h post-transduction and subjected to Western blotting as described in
lls were used as a negative control. The positions of molecular size
efficiency of Bac-G-prM/E and Bac-prM/E. BHK-21 cells were transcuced
and processed for Western blotting analysis.
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50 and 100) and E protein was compared by Western
blot analysis. As shown in Figure 2C, the cells trans-
duced with Bac-G-prM/E showed a darker band than
cells transduced with Bac-prM/E and the protein expres-
sion was increased in a dose-dependent pattern in cells
transduced with both viruses.
Characterization of WNV-specific antibodies elicited by
recombinant baculoviruses in mice
Our previous studies have demonstrated the potential of
using baculovirus as a vaccination platform [29]. To deter-
mine whether the recombinant baculoviruses expressing
prM/E proteins could induce WNV-specific humoral im-
mune responses in vivo, BALB/c mice were immunized
intramuscularly with 109 or 108 PFU/mouse of recombinant
baculovirus. Serum samples were collected at 3 and 6 weeks
after the primary immunization. Then the samples were
diluted 1: 500 and specific IgG responses were determined
by an indirect ELISA using E-DIII protein as coating anti-
gen. At 3 weeks, the antibody titers reached a detectable
level in all the vaccinated groups except the group immu-
nized with the Bac-G-EGFP, Bac-EGFP (control virus) and
PBS, and a further increase in antibody titers were observed
at 6 weeks after primary immunization (p<0.001) (Figure 3).
Mice immunized with 109 PFU of Bac-G-prM/E produced
significantly higher antibody titer than mice received 108
PFU of Bac-G-prM/E (p<0.01). Similar result was also
observed in Bac-prM/E-vaccinated group. Interestingly,
mice immunized with Bac-G-prM/E developed higher anti-
body titer than mice immunized with Bac-prM/E at the
same dosage, but there was no statistical significance
(p>0.05). Immunization with 50μg/mouse of E-DIII pro-
teins induced highest antigen-specific antibody titer. As
expected, all vaccinated groups produced significantly higherFigure 3 WNV-specific ELISA antibody titers in mice immunized with
with recombinant baculovirus Bac-G-prM/E or Bac-prM/E, or control virus, w
materials and methods, mouse immunization). Serum samples were collect
antibodies was analyzed by ELISA at a 1:500 serum dilution. The data are eWNV-specific antibody titers than mice vaccinated with
control viruses (p<0.001).
In order to further study whether recombinant
baculovirus-immunized mice induce WNV-specific neutral-
izing antibodies, serum samples were tested by PRNT. As
shown in Table 1, mice immunized with 108 or 109 PFU of
Bac-G-prM/E or Bac-prM/E developed mean neutralizing
antibody titers of 1:16 and 1:8 or 1:11 and 1:5 at 3 weeks
after primary immunization, which increased further to 1:44
and 1: 22 or 1:30 and 1:12 at 6 weeks, respectively. Although
WNV-specific neutralizing antibodies were detectable in
mice immunized with 50μg of E-DIII protein, the mean
neutralizing antibody titer was 1:8 at 6 weeks, which was
significantly lower than the groups inoculated with 109 PFU
of Bac-G-prM/E and Bac-prM/E (p<0.05). As expected, no
neutralizing antibodies were detected in sera from mice
immunized with control virus or PBS. In addition, we also
determined whether the antibodies can efficiently neutralize
heterologous Japanese encephalitis virus (JEV)-p3 strain. Lit-
tle or none anti-JEV cross-neutralizing antibodies were
detected in sera collected at 3 weeks after the first
immunization. After booster immunization, anti-JEV cross-
neutralizing antibody titers increased to 1:10, which were
lower than those against WNV. These studies indicate that
recombinant baculoviruses immunized mice developed
humoral immune responses evidenced by WNV-specific
neutralizing antibodies and partial anti-JEV cross-
neutralizing antibodies.
WNV-specific cellular immune responses elicited by
recombinant baculoviruses in mice
To further address whether the recombinant baculo-
viruses can elicit cell-mediate immune responses in
mice, mice were immunized with the recombinant bacu-
loviruses and sacrificed at 3 weeks after the boosterrecombinant baculoviruses. Mice were intramuscularly vaccinated
hile E-DIII protein vaccine used as a positive control (for details, see
ed at 3 and 6 weeks after the fist immunization. Presence of
xpressed as average titers per group (n = 6) ± SD.
Table 1 Neutralizing antibody titers in mice immunized
with recombinant baculoviruses (mean values of groups
of 4 mice)
Vaccine Anti-WNVb Anti-JEVc
3 weeks 6 weeks 3 weeks 6 weeks
Bac-G-prM/E 109 16 44 4 10
Bac-G-prM/E 108 8 22 < 2 6
Bac-prM/E 109 11 30 < 2 7
Bac-prM/E 108 5 12 < 2 4
E-DIII pro. 4 8 < 2 < 2
Bac-G-EGFP 109 < 2 < 2 < 2 < 2
Samples were taken three weeks and six weeks after the primary
immunization.a
a plaque-reduction neutralization tests (PRNTs);
b WNV (NY99 strain)-specific neutralizing antibodies; c JEV(P3 strain)-specific
neutralizing antibodies; < 2, not detected.
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nized mice and restimulated in vitro with E-DIII protein.
IFN-γ production was measured by ELISA. As a negative
control, IFN-γ production was also measured upon stimu-
lation of splenocytes with NS3 protein of JEV. Mice immu-
nized with 109 PFU, 108 PFU of Bac-G-prM/E and Bac-
prM/E or 50μg of E-DIII protein showed significantly
higher levels of IFN-γ than mice given the control virus
(109 PFU of Bac-G-EGFP) (Figure 4A). In particular, IFN-γ
level detected in splenocytes of mice inoculated with 109
PFU of Bac-G-prM/E was significantly higher than that in
splenocytes of mice immunized with E-DIII protein
(p<0.01). It was also found that mice immunized with Bac-
G-prM/E developed higher amount IFN-γ than mice re-
ceiving Bac-prM/E, but it was not statistically significant.
Moreover, IFN-γ production in Bac-G-prM/E- or Bac-prM
/E-inoculated group was significant lower when NS3 pro-
tein was used as stimulation antigen and there was no sig-
nificant difference among Bac-G-prM/E, Bac-prM/E, and
control virus immunized group, suggesting WNV specific
IFN-γ production (Figure 4A).
To validate this observation, mRNA level of IFN-γ pro-
duced in splenocytes was further analyzed by real-time
PCR in parallel with the housekeeping gene. Similar to the
results of IFN-γ determined by ELISA, the mean relative
level of IFN-γ mRNA expression showed significant differ-
ence between Bac-G-prM/E- or Bac-prM/E-immunized
mice and Bac-G-EGFP- or E-DIII protein-inoculated mice
(Figure 4B). All these results demonstrate that
immunization with recombinant baculoviruses can stimu-
late cellular immune responses.
Recombinant baculoviruses induce inflammatory
cytokines in mice
To further understand the mechanism associated with
induction of host immune response upon baculovirus in-
oculation, the expression profile of inflammatorycytokines was monitored. Splenocytes from immunized
mice were restimulated in vitro and then mRNA levels
of three inflammatory cytokines, including tumor necro-
sis factor alpha (TNF-α), interleukin-6 (IL-6), and
interleukin-2 (IL-2), were detected by real-time PCR. As
shown in Figure 5, the mean relative mRNA levels of
these inflammatory cytokines in the group immunized
with Bac-G-prM/E or Bac-prM/E were significantly
higher than in the control group. Moreover, mice immu-
nized with 109 PFU of Bac-G-prM/E or Bac-prM/E pro-
duced significantly higher amount of these inflammatory
cytokines than mice immunized with E-DIII protein
(p<0.05). These suggest that a strong inflammatory re-
sponse with a complex pattern of inflammatory cyto-
kines may contribute to the intrinsic immunogenic
properties of the inoculated baculoviruses.
Discussion
WNV continues to present public health threat to the
western hemisphere, yet, there is neither effective ther-
apy nor vaccines available for humans. Thus developing
a safe and effective vaccine is a priority. Several
immunization strategies have been described, some of
which utilize vectored vaccines expressing WNV glyco-
protein E resulted in 80%-100% protective immunity in
animal model [30-34]. In this present study, attempts
were made by using recombinant baculovirus approach
for WNV vaccine development since baculovirus exhibit
low toxoxicity in mammalian cells and can induce inter-
feron production [24]. Two recombinant baculoviruses,
Bac-G-prM/E and Bac-prM/E, expressing the major im-
munogenic protein, glycoprotein E, were constructed,
and the humoral and cellular immune responses were
determined in mice. WNV-specific humoral (WNV-spe-
cific antibodies and neutralizing antibodies) and cellular
immunity (WNV-specific IFN-γ and inflammatory cyto-
kines) were induced in mice inoculated with recombin-
ant baculoviruses. These data are in concordance with
previous studies that showed robust humoral and cellu-
lar immune responses against PRRSV, PCV, or JEV by
recombinant baculoviruses [29].
It has been controversial as to the relative role of the
humoral versus cellular immune responses in the WNV-
protective immunity. High antibody titers are believed to
protect animals against flavivirus infections through dir-
ect neutralization of receptor binding, inhibition of viral
fusion, and/or complement-mediated viral clearance
[35,36]. Neutralizing antibody titers of >1:10 were
reported to be sufficient to afford protection in humans
against JE [37]. Schneeweiss et al. also reported that
mice immunized once with pT-WNV-E produced neu-
tralizing antibodies titer of 1:16 which can protect 100%
of mice from WNV challenge [38]. However, others have
argued that cellular immune responses such as robust
Figure 4 IFN-γ responses induced by immunization with recombinant baculoviruses. (A) Production of IFN-γ in the supernatant of
splenocytes harvested from immunized mice after in vitro restimulation was determined by ELISA. Splenocytes of immunized mice were isolated
6 weeks after the primary immunization and incubated in vitro with E-DIII protein or NS3 protein for 72h. Data represent the mean
concentrations of IFN-γ in the supernatant ± SD of the three independent experiments. (B) IFN-γ relative gene expression in splenocytes
harvested from immunized mice after in vitro restimulation with or without E-DIII protein for 24h. RNA was extracted and subjected to RT-PCR.
Relative quantity of IFN-γ mRNA expression was determined by relative quantitative real-time PCR using β-actin gene as housekeeping gene. The
bars in graph denote the mean relative quantity of IFN-γ mRNA± SD observed from three mice per group, each performed in triplicate. *, p<0.05;
**, p<0.01 compared to the value for 109 PFU of Bac-G-EGFP (control virus)-immunized group.
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WNV [39,40]. In our study, the antibody responses were
evaluated in mice immunized with recombinant baculo-
viruses. Majority of mice immunized with two dosages
of Bac-G-prM/E or Bac-prM/E developed neutralizing
antibodies titers of >1:16 (Table 1). Furthermore, these
baculovirus-derived vaccines can also induce anti-JEV
cross-neutralizing antibodies although the titers of the
antibodies were lower than antibodies against WNV.
These results strongly demonstrate that the antibody re-
sponse induced by WNV protein could partially cross-
neutralize JEV, as has been reported in previous studies[41]. It is reasonable to anticipate that immunization
with these recombinant baculoviruses expressing WNV
antigens will not only provide protection against WNV
infection, but also provide partial protection against JEV
infection. Cellular immunity such as IFN-γ production
and inflammatory cytokines responses were also deter-
mined in mice after immunization with these baculo-
viruses since these cytokines play a critical role in
directing the cell-mediated immune responses [42]. Bac-
G-prM/E- or Bac-prM/E-immunized mice produced
higher levels of IFN-γ than any other group (Figure 4)
and promoted the release of inflammatory cytokines,
Figure 5 Analysis of inflammatory cytokine production following immunization with baculoviruses. Real-time PCR was conducted for three
cytokines, TNF-α, IL-2 and IL-6. Total RNA was obtained as described in Figure 4. The graphs obtained for the expression of TNF-α gene, IL-2 gene and IL-6 gene,
respectively. Data are presented as means±SD (n=3). *, p<0.05; **, p<0.01 compared to the value for 109 PFU of Bac-G-EGFP (control virus)-immunized group.
Zhu et al. Virology Journal 2012, 9:132 Page 7 of 11
http://www.virologyj.com/content/9/1/132including tumor necrosis factor alpha (TNF-α),
interleukin-6 (IL-6), and interleukin-2 (IL-2) (Figure 5).
In this case, secretion of IFN-γ, TNF-α, or IL-2 are indi-
cative of a Th1 response, whereas a Th2 response is
characterized by induction of IL-6 [43]. These indicate
that the recombinant baculoviruses can stimulate both
humoral and cellular immune responses which are
essential to control dissemination of infection and to in-
hibit the entry of virus into brain.
Our results also demonstrate that Bac-G-prM/E exhib-
ited better immunogenicity than Bac-prM/E, as indi-
cated by the higher levels of antibody titers, IFN-γ and
inflammatory cytokines production. It is highly probable
that the expression of VSV/G was associated with
enhancement of the immune responses by augmenting
transduction efficiency of baculovirus into mammalian
cells [20]. In addition, the VSV/G-modified baculovirus
exhibited greater resistance to animal serum inactivation
than the unmodified baculovirus [20], which may con-
tribute to the better immunogenicity of Bac-G-prM/E.
It has been reported that recombinant E-DIII protein
induces high neutralizing antibody titers, as well as pro-
tection against lethal WNV and partial protection against
lethal JEV [41]. Therefore, the recombinant E-DIII protein
of WNV expressed in E.coli was used as a positive control
in the present study. However, intramuscular injection of
mice with E-DIII protein elicited lower levels of
neutralization antibody titers than mice immunized with
the recombinant baculoviruses even at a low dosage (108
PFU/mouse) (Table 1), although the total IgG level was
high (Figure 3). This could be due to differences in experi-
mental designs such as the route of immunization, with or
without adjuvant, and mouse strain. In addition, it has
been shown that E-DIII protein immunization elicits lowlevel of neutralizing antibodies with relatively high IgG
responses [38], which is consistent with our results. It is
noticed that E-DIII protein also induced lower levels of
cellular immune response than recombinant baculo-
viruses, since E protein expressed by recombinant baculo-
virus contains more T cell epitopes than its domain III
[40], and the baculovirus augment cellular immunity.
Baculovirus has been shown to possess a strong adjuvant
activity and to promote humoral and cellular immune
responses for foreign antigens, maturation of dendritic cells,
and production of inflammatory cytokines and IFN [24].
The transduction of macrophages in vitro by baculovirus
led to the induction of significant levels of IL-6 and TNF-α
[44]. It has been proposed that baculovirus genome, espe-
cially its CpG motifs, could be recognized by macrophages
and DCs. Furthermore, baculoviruses enter into the cells
through mannose receptor (MR)-mediated endocytosis or
phagocytosis, leading to the secretion of inflammatory
cytokines through a MyD88/TLR9-dependent signaling
pathway [23,24]. However, Chen et al. reported that recom-
binant baculoviruses are able to induce a robust secretion
of inflammatory cytokines through a TLR3-dependent
pathway [45]. In our study, induction of a measurable IFN-
γ and inflammatory cytokines, including TNF-α, IL-6, and
IL-2 by control baculovirus (Bac-G-EGFP and Bac-EGFP)
was observed, demonstrating that this virus can function
as a stimulator for production of cell-mediate immunity in
an antigen- independent manner (Figure 4). Similar results
have been reported previously that injection with control
baculovirus is capable of inducing IFN-γ responses
[26,27,29]. This is probably due to direct interaction of
baculovirus with dendritic cells and macrophages in the
spleen. Since it has been reported that splenic dendritic cells
and macrophages play a central role in baculovirus-induced
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induced non-specific inflammatory responses raise concerns
that whether they will compromise the use of baculovirus
vectors for in vivo gene therapy in humans and animals.
However, Bac-G-E2 inoculated mice released inflammatory
cytokines as early as 6h post-injection, and returned to back-
ground levels by 48h post-injection [21]. Furthermore, there
was no cytokine-induced acute toxicity or mortality in
baculovirus-immunized mice, which suggests that non-
specific inflammatory responses induced by baculovirus vec-
tors may be minimized by host. Nevertheless, more investi-
gations are needed to ensure the safety of baculovirus
vectors.
The protection is an important index to evaluate the ef-
ficiency of vaccine. However, the ability of our recombin-
ant baculoviruses to protect against lethal challenge of
WNV was not determined in consideration of the safety
problem since WNV has not been found in China. Never-
theless, the neutralizing antibodies and the cellular im-
mune responses induced by recombinant baculoviruses
may provide the basis for protection. Immunization with
baculovirus expressing JEV antigens have been shown to
confer protection against JEV challenge, demonstrating
that cellular immunity plays a crucial role against JEV in-
fection [29]. Thus it is well supported that recombinant
baculoviruses expressing WNV prM/E proteins could pro-
vide protective immunity against WNV challenge.
Methods
Cells, plasmids and virus
Spodoptera frugiperda 9 (Sf9) cells were propagated at 28°
C in Grace’s media (Invitrogen, Carlsbad, CA, USA) sup-
plemented with 10% FBS, 100 μg/ml streptomycin and
100 IU/ml penicillin. BHK- 21 cells, used for transduction
and neutralization tests, were grown and maintained in
Dulbecco’s modified Eagle’s medium (DMEM; Invitrogen,
Carlsbad, CA, USA) supplemented with 10% heated-
inactivated fetal bovine serum (FBS), 100 μg/ml strepto-
mycin and 100 IU/ml penicillin, at 37°C with 5% CO2.
The prM and E genes region (GenBank accession number
DQ211652) corresponding to nt 466–2469, derived from a
North American NY99 strain of WNV, were synthesized
and cloned into pcDNA3.1 vector backbone, to generate
plasmid pcDNA3.1-prM/E. The construction of baculovirus
transfer vector, pFastBac-VSV/G, in which the VSV/G gene
is under the control of the polyhedrin promoter of pFast-
BacTM1 (Invitrogen), was described previously [29]. Bac-G-
EGFP is a pseudotype baculovirus containing a CMV pro-
moter that controls the expression of EGFP [29] and was
used as a control strain of the baculovirus.
Protein and monoclonal antibodies
WNV envelope protein (E protein) domain III (the sequence
corresponding to nt 1858–2211) was expressed in E.coli asan inclusion body, and then purified and refolded in appro-
priate buffer [46]. Protein concentrations were determined
at an absorbance of 280 nm by spectrophotometry. Anti-E-
DIII monoclonal antibody (MAb) was produced from the
mice immunized with E-DIII protein.
Construction of recombinant baculoviruses
To generate the recombinant transfer plasmid pFastBac-G-
prM/E, the DNA fragment containing the prM/E expres-
sion cassette, which was controlled under the CMV pro-
moter, was released from pcDNA3.1-prM/E and inserted
into pFastBac-VSV/G. To generate the recombinant trans-
fer plasmid pFastBac-prM/E the same prM/E expression
cassette was digested and clone into pFastBac1 vector. The
recombinant baculoviruses Bac-G-prM/E and Bac-prM/E
were subsequently generated by using Bac-to-Bac system
(Invitrogen) following the manufacturer’s instructions. The
resultant viruses were further amplified by propagation in
Sf9 cells and purified as described [25]. The virus pellet
was resuspended in phosphate-buffer saline (PBS, PH7.4)
and infectious titers were determined by a plaque assay as
described in the Bac-to-Bac system, and then stored in ali-
quots at −80°C until needed.
Detection of E protein in Baculovirus-transduced cells
The transduction procedure was performed as described
previously with minor modifications [27,29]. BHK-21
cells were seeded into six-well plates at concentration of
1.5 × 105 cells/well. At approximately 70-80% confluence,
culture medium was removed and cells were washed
three times with PBS and incubated with baculoviruses
for 4h at 28°C. After removal of the inoculum, fresh
medium was added and cultures incubated at 37°C for
48h. Duplicate wells were processed in parallel for indirect
immunofluorescence assay and Western blotting. At 48h
after transduction, the cells were fixed with absolute
methanol and processed for the indirect immunofluores-
cence assay using monoclonal antibodies (MAb) against
WNV E-DIII protein, followed by fluorescein isocyanate-
conjugated goat anti-mouse immunoglobulin (Ig) G. For
Western blot analysis, transduced cells were collected at
48h post-transduction and lysed in SDS sample buffer.
Cell extracts were separated by sodium dodecyl sulfate
−10% polyacrylamide gel electrophoresis (SDS-PAGE) and
electroblotted onto a nitrocellulose membrane. The non-
specific antibody binding sites were blocked with 1% bo-
vine serum albumin (BSA) in TBST buffer (10mM Tris–
HCl PH 8.0, 150mM Nacl, and 0.05% Tween-20), and fi-
nally the membrane were reacted with anti-E-DIII Mab to
detect the expressed E protein.
Mouse immunization
Female BALB/c mice (6–8 week old) were purchased
from the Animal Centre, Institute of Medicine, Hubei
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ing to the guidelines of this institution (No. 00020502)
and all experimental protocols were approved by the Re-
search Ethics Committee of College of Veterinary Medi-
cine, Huazhong Agricultural University, Hubei, China.
Then the mice were randomly divided into eight groups
(6 mice per group). Two groups were injected intramus-
cularly (i.m.) with 100μl of PBS containing 1 × 108 or
1 × 109 PFU of Bac-G-prM/E and another two groups
were immunized with Bac-prM/E. The other three
groups were injected intramuscularly with 100μl of PBS
containing 1 × 109 PFU of Bac-G-EGFP, Bac-EGFP, and
100μl of PBS containing 50μg of E-DIII protein, respect-
ively. The last group was used as a negative control by
intramuscularly injecting 100μl of PBS. Booster immuni-
zations were identically performed 3 weeks later. Serum
samples were collected from the tail vein of 6 individual
mice before the second injection and from the retro-
orbital plexus at 6 weeks after primary immunization
and then store at −20°C for serological tests. At 6 weeks
after the primary immunization, three mice of each
group were euthanized, and splenocytes were harvested
for immunological assay.
Antibody assay
Induction of E protein-specific antibody was determined
by using indirect enzyme linked immunosorbent assay
(ELISA). Microplates were coated with E-DIII protein
(20ng/well) overnight at 4°C [38]. After blocking for 1h
at 37°C with PBST (2% bovine serum albumin, PBS,
0.05% Tween 20) to avoid nonspecific binding, serum
diluted in PBST (1:500) were added to each well and
incubated at 37°C for 1h. After washing with PBST,
bounded proteins were detected with HRP conjugated
with goat anti-mouse IgG (Boster, China). Serum anti-
body titer was monitored versus optical density values.
The endpoint titers of the neutralizing antibodies against
WNV and JEV were determined by plaque-reduction
neutralization tests (PRNTs) using WNV strain NY99
and JEV strain P3, in biosafety level–3 conditions,as
described earlier [47]. Briefly, serum samples were heat-
inactivated for 45min at 56°C and then serially diluted
and mixed with an equal volume containing 100 PFU ofTable 2 Relative quantitative real-time PCR primers for target
Targeted
transcriptsa







a Mouse derived targeted transcripts. bHouse keeping gene for internal control.virus. The mixtures were incubated for 1h at 37°C and
then inoculated onto BHK-21 cell monolayers in 12-well
plates. After adsorption for 1h at 37°C, the wells were
overlaid with medium containing 1.5% carboxymethyl
cellulose, and the plates were incubated in a 5% CO2 in-
cubator at 37°C for 3–4 days for plaque formation, then
fixed with 10% formalin in PBS. Plates were washed and
stained with 0.01% crystal violet. The percent plaque re-
duction was calculated relative to virus controls without
serum. The PRNT titers were given as the reciprocal of
the highest serum dilutions which resulted in> 50% re-
duction of the plaques.
IFN-γ detection
Mouse splenocytes were prepared from immunized mice
and resuspended in RPMI 1640 (Invitrogen, Carlsbad,
CA, USA) supplemented with 10% FBS, 2mM L-glutam-
ine, 100μg/ml streptomycin and 100 IU/ml penicillin.
Splenocytes (1 × 106/ml) were cultured in 24-well plates
at 37°C in the presence of 20μg/ml WNV E-DIII or JEV
NS3 protein. After 72h incubation, culture supernatant
was harvested and the presence of IFN-γ was measured
with commercial mouse IFN-γ immunoassay ELISA kits
(eBioscience Inc., San Diego, CA) according to the man-
ufacture’s guidelines. The concentrations of IFN-γ in the
samples were calculated from the standard curves.
Analysis of cytokine mRNA expression by Real-time PCR
Mouse splenocytes (1 × 106/ml) were maintained in 24-
well plates for 20h at 37°C in the presence of 5% CO2,
with or without 20μg/ml E-DIII protein. Total RNA
from each immunized group was extracted using Trizol
(Invitrogen) in accordance with the manufacture’s guide-
lines. RNA concentrations were determined by OD260
measurements and 1μg of RNA was reverse transcribed
using the Rever Tra AceTM kit (ToYoBo, China) in a
20μl reaction mixture. Afterward, the cDNA pool (0.5μl)
was amplified in a 25μl reaction mixture containing
SYBRTM Green real-time Master Mix (ToYoBo, China)
and 0.2μM each of the forward and reverse gene-specific
primers (listed in Table 2), aliquoted into 96-well plates
(Axygen, CA, USA), and then sealed with optical sealing
tape (Axygen, CA, USA). Real-time PCR was performeded transcripts mRNAs
Conditions
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time PCR System and universal cycle conditions (2min
at 50°C, 10min at 94°C, 40 cycles of 15s at 94°C and then
1min at 60°C). House keeping gene β–actin was mea-
sured in parallel, which was used as the internal control.
In order to evaluate the expression of the target gene by
relative quantity, the threshold cycle (Ct) of the sample
of interest was compared to the Ct generated by a refer-
ence sample referred to as the calibrator (a sample from
nonstimulated splenocytes). Cytokine gene expression
was normalized to β–actin expression by the subtraction
of Ct to provide ΔCt values. The ΔΔCt was calculated as
the difference between ΔCt values for stimulated and
nonstimulated splenocytes (the calibrator). Thus, the
relative difference in cytokine expression between stimu-
lated and nonstimulated cells was calculated as fold
change by using equation 2-ΔΔCt.
Statistical analysis
Where specified, an unpaired t-test was used to compare
the humoral and cellular immune responses between the
different groups. All comparisons were made using two-
tailed and P-values of 0.05 or less were considered statis-
tically significant.
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